Survival Prolongation by Rationale Innovative Genomics (SPRING)

• ClinicalTrials.gov Identifier: NCT03386929
• Recruitment Status: Terminated
• First Posted: December 29, 2017
• Last Update Posted: January 26, 2023
• Sponsor: Worldwide Innovative Networking Association
• Collaborators: ARC Foundation for Cancer Research; Pfizer
• Information provided by (Responsible Party): Worldwide Innovative Networking Association

Study Description

Brief Summary:

Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if available or MET exon 14 skipping mutation if available) will receive a tri-therapy associating avelumab, axitinib and palbociclib.

Condition or disease	Intervention/treatment	Phase
Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage III	Drug: Avelumab; Drug: Axitinib; Drug: Palbociclib	Phase 1; Phase 2

Detailed Description:

During the Phase 1 (approximately 30 patients), the tri-therapy will be tested at different doses following a specific dose-escalation scheme (3 + 3 model) in order to establish the safety and identify the Maximum Tolerated Dose (MTD) and recommended dose (RP2D) for the Phase 2. The phase 2 will confirm the safety and will assess the clinical utility of the tri-therapy approach in the treatment of advanced/metastatic NSCLC (100 patients). The study will also explore the clinical utility of the Simplified Interventional Mapping System (SIMS), a new tool/algorithm enabling matching of NSCLC patients with combination therapy. For this purpose tumor/metastasis and matched normal tissue biopsies will be requested in order to obtain sequencing and expression profiles.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 15 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Proof of Concept Study to Explore Safety and Efficacy of Tri-therapy Approach in Advanced/Metastatic NSCLC and Retrospectively Assess the Ability of Integrated Genomics and Transcriptomics to Match Patients to the Combination
• Actual Study Start Date: November 29, 2017
• Actual Primary Completion Date: December 29, 2022
• Actual Study Completion Date: December 29, 2022

Arms and Interventions

Arm

Intervention/treatment

Experimental: Avelumab, Axitinib, Palbociclib; For the Phase 1: Avelumab is administered intravenously (IV) on Day 1 and Day 15 of each Cycle (one cycle = 28 days) in combination with axitinib po bid and palbociclib po (7 days off; 21 days on). For the Phase 2: Avelumab, axitinib and palbociclib are administered at the recommended dose (RP2D) as determined during the phase 1 part of the study.

Drug: Avelumab; A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.; Other Name: Bavencio; Drug: Axitinib; A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.; Other Name: Inlyta; Drug: Palbociclib; A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.; Other Name: Ibrance

Outcome Measures

Primary Outcome Measures :

1. Dose Limiting Toxicity (DLT) [ Time Frame: Cycle 1 Days 1-28 (28 days from date of first dose of study treatment) ]
   DLT is assessed by NCI CTCAE v4.03
2. Incidence of the tested 3-Drug Combination Therapy-Emergent Adverse Events and Serious Adverse Events [ Time Frame: From informed consent signature through 90 days after administration of the treatment (last dose) ]
   The occurrence of adverse events and serious adverse events reported from the signing of an informed consent through 90 days after the last administration of the treatment will be summarized for all subjects who received at least one dose of the study treatment (safety population) and will be evaluated based on NCI CTCAE v4.03: June 14, 2010.
3. Response Rate (RR) [ Time Frame: Baseline up to approximately 24 months ]
   Response rate is defined as the proportion of participants with reduction in tumor burden of a predefined amount based on RECIST 1.1 evaluation
4. Duration of the Response [ Time Frame: Baseline up to approximately 24 months ]
   Duration of Response (DR) is defined for patients with confirmed objective response (Complete Response [CR] or Partial Response [PR]) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.
5. Progression-Free Survival (PFS) [ Time Frame: Baseline up to approximately 24 months ]
   Progression Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression by RECIST 1.1 or death due to any cause, whichever occurs first.
6. Overall Survival (OS) [ Time Frame: Baseline up to approximately 24 months ]
   OS is defined as the time from the first dose of study treatment to the date of death due to any cause.
7. SIMS Algorithm to Predict Clinical Outcome [ Time Frame: 4 years ]
   The proportion of participants whose SIMS analysis matches the treatment combination, will be correlated retrospectively to clinical outcome.

Secondary Outcome Measures :

1. Incidence of Treatment-related and or Biopsy-related Serious Adverse Events [ Time Frame: 4 years ]
   The occurrence of treatment-related and or biopsy-related serious adverse events as assessed by NCI CTCAE v4.03 will be summarized for all study subjects.
2. Genomic and Transcriptomic Profile [ Time Frame: 4 years ]
   Genomic (DNA) and transcriptomic (RNA) aberrations (mutations, translocations, rearrangements and changes in expression level) identified in the study population (Non-Small Cell Lung) will be described.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

ELIGIBILITY CRITERIA

• Age: Men and women aged >18 years,
• Signed written informed consent,
• Any histologic type of locally advanced or metastatic NSCLC,
• Life expectancy of ≥ 12 weeks,
• Measurable or evaluable (cytologically or radiologically detectable disease such as ascites, peritoneal deposits, or lesions which do not fulfill RECIST 1.1 criteria for measurable disease) lesions according to RECIST 1.1 criteria for phase 1 portion. For phase 2, all patients must have RECIST 1.1 measurable disease,

• Physiologic function:

  • Hematologic: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, and hemoglobin ≥ 9 g/dL (may have been transfused),
  • Hepatic: Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN,
  • Renal: Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).

• Pregnancy and contraception:

  • Pregnancy test: Negative serum or urine pregnancy test at screening for women of childbearing potential.
  • Contraception: Highly effective contraception for both male and female subjects throughout the study and for at least 90 days after last treatment administration if the risk of conception exists.
• Ability to comply with protocol requirements,
• Willingness to consent and ability to undergo a trucut biopsy to obtain a fresh metastasis or primary tumor biopsy, and to undergo bronchoscopy to obtain a biopsy from normal bronchial mucosa,
• No serious or medically uncontrolled concomitant conditions that are likely to make the patient unfit for SPRING combination therapy, as per investigator assessment,
• ECOG performance status of 0 to 1.

EXCLUSION CRITERIA

• Patients with documented oncogenic aberrations at enrollment: EGFR, ALK, ROS1 when available, MET exon 14 skipping when available. For squamous undifferentiated cell carcinoma, documentation of these aberrations is not mandatory. Note: For Phase 1 portion, all patients with adenocarcinoma histology must have documentation of results for druggable oncogenic aberrations (EGFR mutations, ALK rearrangements, and ROS1 when available) prior to enrollment on the study.
• For Phase 1 portion, >2 lines of prior therapy in the metastatic setting.
• For the dose escalation phase of the study or until the MTD for the combination regimen has been determined, patients with moderate hepatic impairment defined as AST, ALT, alkaline phosphatase (ALP) >5 times ULN, which would be grade 3 or higher. However, patients with liver metastases with AST/ALT ≤ 5 x ULN can be included in the study.
• For Phase 2 portion, any prior therapy in the metastatic setting.

Clinical criteria for phase 1 and phase 2 studies:

• Patients with treated brain metastases are eligible as are patients with new, active untreated brain metastasis.
• Participants with a history of myocardial infarction within the last 2 years or with significant cardiac arrhythmias uncontrolled by medication or pacemaker,
• Participants with any history of interstitial lung disease,
• Prior clinically significant toxicities from anticancer agents or radiotherapy which have not regressed to Grade ≤ 1 severity (NCI-CTCAE version 4.03) apart from peripheral neuropathy and alopecia,
• History of any second malignancy in the last two years; patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least two years,
• Autoimmune condition requiring medical intervention,
• Uncontrolled concomitant illness, active infection requiring i.v. antibiotics,
• Patients who have had a thromboembolic event within six months are excluded, as are patients on anticoagulants, except for low dose aspirin (<100 mg/day) and low doses of anticoagulants meant to keep line access open;
• Patients with Grade 3 or 4 (serious) gastrointestinal bleeding within the last six months are excluded.
• Prior > G3 hemoptysis, major blood vessel involvement (specifically including aorta, superior and inferior vena cave, main pulmonary arteries and veins, subclavian arteries and veins and other large blood vessels that in the investigator's opinion places the patients at high risk for major bleeding), and/or central cavitations,
• Known or suspected drug hypersensitivity to any drug used in the combination,
• Difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the oral drugs,
• Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc.) that, in the judgment of the investigator may affect the patient's ability to sign the informed consent and undergo study procedures,
• Taking another experimental drug within 28 days prior to day 1 of the protocol medications in this study,
• Pregnant or breast-feeding women,
• Both male and female patients of reproductive potential must agree to use highly effective contraception, during the study and for 3 months following the last dose of study drug,
• Patients currently taking strong CYP3A4 inducers and inhibitors,
• Patients currently taking proton pump inhibitors due to their impact on the disposition of palbociclib during the phase 1.
• Patients taking other anticancer agents with the exception of denosumab or equivalent medication for bone metastases.
• A time period of at least three weeks (including radiotherapy) or five drug half-lives, whichever is shorter must have elapsed from last non-investigational therapy before first day of treatment on this study,
• A time period of at least 10 days must have elapsed from last palliative radiotherapy before the first day of treatment on this study,

• Specific exclusion criteria for administration of avelumab, in combination:

  • IMMUNOSUPRESSANTS: Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
  • AUTOIMMUNE DISEASE: Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
  • ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell transplantation.
  • INFECTIONS: Active infection requiring IV (Intra venous) therapy.
  • HIV/AIDS: Known history of testing positive for HIV or known acquired immunodeficiency syndrome.
  • HEPATITIS: Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
  • VACCINATION: Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
  • HYPERSENSITIVITY TO STUDY DRUG: Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3).
  • CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia inadequately controlled by medication.
  • OTHER PERSISTING TOXICITIES: Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
  • Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Contacts and Locations

Locations

United States, California

UCSD Moores Cancer Center

La Jolla, California, United States, 92093

United States, South Dakota

Avera Cancer Center

Sioux Falls, South Dakota, United States, 57105

Israel

Chiam Sheba Medical Center

Ramat Gan, Israel, 5265601

Luxembourg

Centre Hospitalier Luxembourg

Luxembourg, Luxembourg, 1210

Spain

Vall Hebron Institute of Oncology

Barcelona, Spain, 08035

Sponsors and Collaborators

Worldwide Innovative Networking Association

ARC Foundation for Cancer Research

Pfizer

Investigators

• Principal Investigator: RAZELLE KURZROCK, MD; University of California, San Diego

More Information

Additional Information:

sponsor website 

SIMS article link: A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 Jul;11(14):2790-2800. doi: 10.1002/cam4.4635. Epub 2022 Mar 20.

• Responsible Party: Worldwide Innovative Networking Association
• ClinicalTrials.gov Identifier: NCT03386929
• Other Study ID Numbers: WIN001; 2017-001455-32 ( EudraCT Number )
• First Posted: December 29, 2017
• Last Update Posted: January 26, 2023
• Last Verified: January 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Worldwide Innovative Networking Association:

NSCLC; tri-therapy; avelumab; axitinib; palbociclib; dual matched normal and tumor biopsies; SIMS algorithm; Sequencing; Gene expression

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Palbociclib; Avelumab; Axitinib; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents, Immunological